Getinge will gradually phase out its surgical perfusion business, to focus on more profitable growth areas such as ECLS and ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.

Global Organ Preservation IndustryThe global organ preservation market is poised for steady expansion, with its value ...

Normothermic machine perfusion (NMP) to preserve livers prior to transplant was associated with significantly improved ...

Stifel analysts maintained a Buy rating and a $72.00 price target for LivaNova (NASDAQ:LIVN), following news from Swedish ...

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the completion of the world's first-in-human cases utilizing its FDA-cleared ...

LivaNova (LIVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from ...

Press release Gothenburg, Sweden on January 28, 2025 "In 2024, Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, als ...

With a substantial 34% earnings before interest, taxes, and amortization beat in the fourth quarter, Getinge reported a ...

The data revealed that the use of the Trans-Arterial Micro-Perfusion (TAMP) device resulted in greater drug potency and fewer ...